|
What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy
|
|
Toward personalized treatment in Waldenström macroglobulinemia
|
|
Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemia
|
|
MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival
|
|
Novel approaches to targeting MYD88 in Waldenström macroglobulinemia
|
|
The importance of the genomic landscape in Waldenström’s Macroglobulinemia for targeted therapeutical interventions
|
|
Comparative outcomes of immunochemotherapy regimens in Waldenstrom macroglobulinaemia
|
|
CXCL13 levels are elevated in patients with Waldenstrom's Macroglobulinemia, and are predictive of major response to ibrutinib
|
|
Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia
|
|
Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia
|
|
Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia
|
|
Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel
|
|
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
|
|
Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214)
|
|
Future therapeutic options for patients with Waldenström macroglobulinemia
|
|
Epigenomics in Waldenstrom's macroglobulinaemia
|
|
MYD88 mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinaemia
|
|
Guideline for the diagnosis, treatment, and response criteria for Bing Neel Syndrome
|
